Bausch Health Gets FDA Approval for Acne Treatment Cabtreo
Provided by
Dow Jones
By Ben Glickman
Bausch Health Cos. has received approval from the Food and Drug Administration for Cabtreo, its topical gel for acne.
The Laval, Quebec-based pharmaceutical company said the treatment, which combines clindamycin phosphate, adapalene and benzoyl peroxide, is expected to become available in the first quarter of 2024.
The approved new drug application allows for the use of Cabtreo in treating acne vulgaris in patients 12 years and older.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
October 20, 2023 17:50 ET (21:50 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks
United States